Mengchao Hepatobiliary Hospital of Fujian Medical University

4 results · Page 1 of 1

Swipe the table sideways for more columns.

Trial	Conditions	Status	Phase	Updated	NCT ID
Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) and Compensated Cirrhosis	Digestive System Diseases, Fibrosis, Pathologic Processes, Pathological Conditions, Signs and Symptoms, bile duct disorder, biliary tract disorder, cholestasis, cirrhosis of liver, intrahepatic cholestasis, liver disorder, primary biliary cholangitis	Recruiting	Phase 3	2026-10-06	NCT06051617
A Phase 3 Study Evaluating Efficacy and Safety of Lanifibranor Followed by an Active Treatment Extension in Adult Patients With (NASH) and Fibrosis Stages F2 and F3 ( NATiV3 )	Digestive System Diseases, Fibrosis, Pathologic Processes, Pathological Conditions, Signs and Symptoms, fatty liver disease, liver disorder, metabolic dysfunction-associated steatohepatitis, metabolic dysfunction-associated steatotic liver disease	Active, not recruiting	Phase 3	2026-07-02	NCT04849728
A Study to Evaluate Efficacy and Safety of Hepatic Resection for Liver Cancer With PVTT, HVTT or IVCTT After Initial Ate/Bev	Embolism and Thrombosis, Venous Thrombosis, cardiovascular disorder, thrombotic disease, vascular disorder	Active, not recruiting	Phase 3	2026-01-15	NCT04649489
CT011 Autologous CAR-T Cells in Patients With Hepatocellular Carcinoma at Risk of Recurrence After Surgical Resection	hepatocellular carcinoma	Recruiting	Phase 1	2024-08-19	NCT06560827

Clinical trials